Observational studyScientific reports2025
Quality of life and clinical data in hemodialysis patients with different degrees of pruritus.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease-associated pruritus (CKD-aP), a persistent itching sensation, is prevalent among hemodialysis patients. This study aims to understand its prevalence, its possible association with selected solutes, and impact on quality of life (QoL) in hemodialysis patients. Involving 434 hemodialysis patients in Spain, this observational study employed a survey based on validated pruritus assessment tools, alongside demographic, clinical, and biochemical data collection. The study used statistical analyses to examine the correlation between CKD-aP and various QoL dimensions. CKD-aP affected 46,4% (202) of the participants, with no significant variation across gender and age (p = 0.222 and p = 0.379, respectively). There were no significant associations between CKD-aP and biochemical markers like calcium, phosphate, and C-reactive protein (p > 0.05, in all cases). Each reporting period (morning, midday, evening, and night) revealed distinct patterns in pruritus prevalence and severity (p < 0.05). The nighttime report exhibited the most significant differences, as more than half of the patients with moderate to severe pruritus reported constant and frequent itching (23.0% and 27.9%, respectively). Concerning other variables and symptoms associated with QoL, pruritus group exhibited higher rates of anxiety, depression, decreased sexual desire and sexual function, and sometimes to most of the time reported sleep onset problems, sleeping pill use, and drowsiness on waking (p < 0.001 in all cases). When stratifying by pruritus intensity differences persisted across anxiety (p < 0.001) and sleep onset problems (p = 0.018). The findings underscore the high prevalence and severe impact of CKD-aP in QoL among hemodialysis patients, indicating a need for standardized screening and treatment approaches in clinical practice. The lack of correlation with common biochemical markers suggests an intricate pathophysiology, warranting further investigation. These insights emphasize the necessity of holistic management strategies and more research to understand CKD-aP complex nature for better patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.